45
Building these models took a few months, but Pak says they were very quick at designing candidates for therapies once the setup was complete: “I think it was a day or half a day, something like that.”
Zou says the agents decided to study anti-covid nanobodies, a cousin of antibodies that are much smaller in size and less common in the wild. Zou was shocked, though, at the reason. He claims the models landed on nanobodies after making the connection that these smaller molecules would be well-suited to the limited computational…